In Trump’s Fentanyl War, One Biotech Offers a Potential Solution

President Trump has made his stance clear.

“I will not stand by and allow our citizens to be poisoned.”

Under his leadership, fentanyl has been elevated to a national security threat. Cartels have been designated as terrorist organizations.

And the HALT Fentanyl Act permanently classified fentanyl-related substances as Schedule I drugs.

The message from Washington is unmistakable: prevention is now a national priority.

And the numbers explain why. Every day, more than 200 Americans die from overdose, a toll that cost the economy more than $2.7 trillion in 2023 alone.

ARMR Sciences believes it can answer the call.

The company is developing the first preventive immunotherapy designed to neutralize fentanyl before it can cause an overdose.

Unlike Narcan and other reactive treatments that only work after an overdose begins, ARMR’s approach is being developed to be proactive.

In preclinical trials, its lead candidate, ARMR-100, blocked 92% of fentanyl from reaching the brain and eliminated 100% of its addictive behavioral effects. Results that no other potential solution has come close to achieving.

These results are not by chance. They are backed by six years of Department of Defense-funded research and a proven team that has already successfully advanced countermeasures for Ebola, Anthrax, and Dengue Fever.

And now, for the first time, investors can join this mission before their planned IPO.

Through ARMR’s Series A Preferred Stock, investors can get a 7% annual dividend today and a 25% discount when shares convert in the event of a future IPO.

• 7% annual dividend until public listing
• Automatic conversion to common stock at IPO at 25% discount to IPO share price
• NASDAQ ticker reserved: “ARMR”
• Targeted public listing in 2026, subject to market conditions

President Trump has made it clear that fentanyl is not only a public health crisis but a national security threat. Washington is backing prevention, and ARMR believes it’s advancing the type of breakthrough that could help define the next wave of American biodefense.

For a limited time, investors can purchase Series A Preferred Stock in ARMR before this round closes.

Allocation is limited; click here to participate.

This is paid advertising for ARMR Sciences' private placement offering. ARMR Sciences is currently undertaking a private placement offering pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"), and/or Rule 506(c) of Regulation D promulgated thereunder. Investors should consider the investment objectives, risks, and investment time horizon of the Company carefully before investing. The private placement memorandum relating to this offering of equity interests by the Company will contain this and other information concerning the Company and the securities referenced in this document, including risk factors, which should be read carefully before investing. You should be aware that (i) the securities may be sold only to "accredited investors," as defined in Rule 501 of Regulation D; (ii) the securities will only be offered in reliance on an exemption from the registration requirements of the Securities Act and will not be required to comply with specific disclosure requirements that apply to registration under the Securities Act; (iii) the United States Securities and Exchange Commission will not pass upon the merits of or give its approval to the securities, the terms of the offering, or the accuracy or completeness of any offering materials; (iv) the securities will be subject to legal restrictions on transfer and resale and investors should not assume they will be able to resell their securities; investing in these securities involves a high degree of risk, and investors should be able to bear the loss of their entire investment. Furthermore, investors must understand that such investment could be illiquid for an indefinite period of time.

The offering documents may include "forward-looking statements" within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor provisions for forward-looking statements. This information is supplied from sources we believe to be reliable, but we cannot guarantee accuracy. Although we believe our expectations expressed in such forward-looking statements are reasonable, we cannot assure you that they will be realized. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, but not limited to the risks and uncertainties set forth in the attached materials, which could cause actual results to differ materially from the anticipated results set forth in such forward-looking statements. Any forward-looking statement made by us speaks only as of the date on which it is made, and we undertake no obligation to publicly update any forward-looking statement except as may be required by law.

The Company is "Testing the Waters" under Regulation A under the Securities Act of 1933. The Company is not under any obligation to make an offering under Regulation A. No money or other consideration is being solicited in connection with the information provided, and if sent in response, will not be accepted. No offer to buy the securities can be accepted and no part of the purchase price can be received until an offering statement on Form 1-A has been filed and until the offering statement is qualified pursuant to Regulation A of the Securities Act of 1933, as amended, and any such offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time before notice of its acceptance given after the qualification date. Any person's indication of interest involves no obligation or commitment of any kind. The information in that offering statement will be more complete than the information the Company is providing now, and could differ materially. You must read the documents filed. No offer to sell the securities or solicitation of an offer to buy the securities is being made in any state where such offer or sale is not permitted under the "blue sky" or securities laws thereof. No offering is being made to individual investors in any state unless and until the offering has been registered in that state or an exemption from registration exists therein. The securities offered using Regulation A are highly speculative and involve significant risks. The investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that such investment could be illiquid for an indefinite period of time. No public market currently exists for the securities, and if a public market develops following the offering, it may not continue. The Company intends to list its securities on a national exchange and doing so entails significant ongoing corporate obligations including but not limited to disclosure, filing and notification requirements, as well compliance with applicable continued quantitative and qualitative listing standards.